Antonio Palumbo

820 total citations · 1 hit paper
5 papers, 451 citations indexed

About

Antonio Palumbo is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Antonio Palumbo has authored 5 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Hematology. Recurrent topics in Antonio Palumbo's work include Multiple Myeloma Research and Treatments (5 papers), Cancer Treatment and Pharmacology (4 papers) and Protein Degradation and Inhibitors (3 papers). Antonio Palumbo is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Cancer Treatment and Pharmacology (4 papers) and Protein Degradation and Inhibitors (3 papers). Antonio Palumbo collaborates with scholars based in Netherlands, Italy and United States. Antonio Palumbo's co-authors include Francesca Gay, Paul G. Richardson, Cyrille Hulin, Sin‐Ho Jung, Zhinuan Yu, Benjamin Winograd, Robert Knight, Sara Bringhen, Patrizia Tosi and Gérald Marit and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Antonio Palumbo

5 papers receiving 444 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017 392 citations Philip L. McCarthy, Sarah A. Holstein et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Antonio Palumbo

Since Specialization

Citations

This map shows the geographic impact of Antonio Palumbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Palumbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Palumbo more than expected).

Fields of papers citing papers by Antonio Palumbo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Palumbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Palumbo. The network helps show where Antonio Palumbo may publish in the future.

Co-authorship network of co-authors of Antonio Palumbo

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Palumbo. A scholar is included among the top collaborators of Antonio Palumbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Palumbo. Antonio Palumbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence 2024 ·British Journal of Haematology ·(unknown), Katja Weisel, (unknown), John A. Carter, Simon McNamara, (unknown), Antonio Palumbo, Paul G. Richardson	9
2	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis breakdown → 2017 ·Journal of Clinical Oncology ·Philip L. McCarthy, Sarah A. Holstein, Maria Teresa Petrucci, Paul G. Richardson, Cyrille Hulin, Patrizia Tosi, Sara Bringhen, Pellegrino Musto, Kenneth C. Anderson, D. Caillot, Francesca Gay, Philippe Moreau, Gérald Marit, Sin‐Ho Jung, Zhinuan Yu, Benjamin Winograd, Robert Knight, Antonio Palumbo, Michel Attal	392
3	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. 2016 ·Journal of Clinical Oncology ·Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, María‐Victoria Mateos, Tomer M. Mark, Ming Qi, Jordan M. Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld	2
4	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). 2016 ·Journal of Clinical Oncology ·Michèle Cavo, Antonio Palumbo, Sonja Zweegman, Meletios Α. Dimopoulos, Roman Hájek, Lucia Pantani, Meral Beksaç, Ruth Wester, Hans Erik Johnsen, Ulf‐Henrik Mellqvist, Maria Teresa Petrucci, Christoph Driessen, Francesco Di Raimondo, Rossella Troia, Annalisa Pezzi, Bronno van der Holt, Ka Lung Wu, H Ludwig, Francesca Gay, Pieter Sonneveld	47
5	Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network 2014 ·Blood ·Pieter Sonneveld, (unknown), Bronno van der Holt, Sonja Zweegman, (unknown), Edo Vellenga, Marinus van Marwijk-Kooy, Okke de Weerdt, Sarah Lonergan, Antonio Palumbo, Henk M. Lokhorst	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact